MENLO PARK, Calif.--(BUSINESS WIRE)--Velomedix, a venture-backed medical device company advancing the field of therapeutic hypothermia, today announced the enrollment of the first patient in its VELOCITY pilot study. VELOCITY is a prospective, randomized, multi-center study designed to further evaluate the safety and feasibility of the Velomedix rapid therapeutic hypothermia system in patients with acute myocardial infarction (AMIs or heart attacks). The first patient was enrolled by David Shavelle, M.D., at the University Of Southern California Keck School Of Medicine in Los Angeles, CA.
